News – AU – GenesisCare and PreludeDx ™ Partner to Bring Access to Breakthrough Precision Testing for Women with Early Breast Cancer


SYDNEY & LAGUNA HILLS, Calif .– (BUSINESS WIRE) – GenesisCare, a global leader in integrated cancer care, and Prelude Corporation (PreludeDxTM), a leading provider of molecular diagnostics and precision medicine, today have a new strategic partnership announced, which aims to improve access to personalized breast cancer care and improve patient outcomes

DCISionRT® is a precision test for women diagnosed with DCIS (ductal carcinoma in situ) or stage 0 breast cancer who are being treated with breast-conserving surgery.The DCISionRT test developed by PreludeDx assesses a woman’s 10-year risk for one Recurrence of DCIS or the development of invasive breast cancer The test provides predictive information about the risk of recurrence, so doctors can better select patients who will benefit from radiation therapy in addition to surgery

Patients with DCIS have abnormal cells that line the milk ducts of the breast and have not spread to the surrounding breast tissue, according to a March 2020 report by the US National Center for Biotechnology Information, 20 percent of all breast cancers DCIS1 in Australia are women, with diagnosed with DCIS have an average of 39 times more likely to develop invasive breast cancer than similar-aged Australian women without DCIS2. DCISionRT helps doctors better identify patients with elevated levels and inform patients about whether radiotherapy in addition to surgery increases the risk of DCIS recurrence or an invasive disease3

The new partnership between GenesisCare and PreludeDx will make DCISionRT tests available in Australia, where the test is not currently offered, and improve patient access in the US through GenesisCare’s network of integrated cancer treatment centers. GenesisCare, headquartered in Australia, is one of the largest networks for integrated Oncology care worldwide with more than 440 treatment centers and clinics in the US, Australia, the UK and Spain

Through the partnership, GenesisCare and Prelude will also explore the clinical development of precision medicine tests for breast or other cancers with global real-world evidence. GenesisCare, through its contract research organization, will leverage its global network of physicians and clinical research expertise to enhance the existing U.S. Expand the Prelude registry to Australia and advance and evaluate the impact of DCISionRT on decision-making in the treatment of women with DCIS

Dan Collins, Founder and Global Chief Executive Officer of GenesisCare, said, “GenesisCare is excited to bring this much-needed test to early-stage breast cancer patients in Australia and the US”

“Over the past decade we have observed the profound positive effects of precision medicine on the quality of life of cancer patients by personalizing the therapeutic pathway to a person’s tumor and risk factors”

“The innovative DCISionRT test heralds a new era in the provision of precise cancer treatments We are excited to be at the forefront of bringing this latest advancement in personalized medicine to early-stage breast cancer patients around the world ”

“Our new global partnership with PreludeDxTM will provide thousands of women with information about their own biological risk factors and enable clinicians and patients to make more informed decisions about their treatment options,” said Mr. Collins

Daniel Forche, President and Chief Executive Officer of PreludeDx, said, “We share GenesisCare’s mission to treat every cancer patient as an individual and are excited to work with GenesisCare to improve patient access to DCISionRT”

“This partnership is an important milestone as it is the first time DCIS patients in Australia will have access to personalized information to help them better decide whether surgery alone or surgery with radiation therapy is appropriate”

“This partnership will also leverage GenesisCare’s international network outside of the US to rapidly expand our real-world data registry, and we appreciate the clinical evidence we can provide to patients, doctors, governments and payers,” said Mr. Forche

GenesisCare’s Global Chief Medical Officer, Dr Wally Curran said, “In the past, clinicians have relied on clinical information and pathology to determine treatment plans for women with DCIS Now we can use molecular information from each patient’s cancer to personalize treatment plans with unmatched confidence. We know that there is significant variation around the world in treating DCIS patients with radiation therapy combined with surgery ”

“This test balances the diagnostic playing field for DCIS patients and enables clinicians and patients to make more informed decisions about treatment options based on a patient’s individual biological risk profile,” said Dr Curran

GenesisCare, headquartered in Sydney, treats people with cancer and heart disease, the world’s two largest disease burdens.We are committed to driving change in the way we care and are currently conducting or participating in more than 150 clinical trials The organization employs more than 5500 highly trained doctors, healthcare professionals and support staff in Australia, Europe and now the USAS This follows our acquisition of Major US. Integrated Oncology Provider 21st Century Oncology in May 2020 Every year, GenesisCare’s clinical teams see more than 400000 people in more than 440 locations Cancer treatment includes more than 300 locations in the USAS38 locations in Australia, 14 in the UK and 21 in Spain More than 30 new centers are under development We also offer cardiology and sleep services in more than 80 locations across Australia Our goal is to develop care experiences that produce the best possible life outcomes We believe that care is centered on the individual and shouldn’t focus on the condition, and pride ourselves on our world-class patient satisfaction ratings. For more information, please visit wwwGenesiscarecom

DCISionRT is the only risk assessment test for patients with ductal cancer in situ (DCIS) that predicts the benefit of radiation therapy.Patients with DCIS have cancer cells that line the milk ducts of the breast but have not spread to the surrounding breast tissue every year in the US over 60000 women newly diagnosed with DCIS DCISionRT, which was developed by PreludeDx based on technology licensed from the University of California at San Francisco and based on research that began with funding from the National Cancer Institute, enables doctors to understand the biology of DCIS better understand DCISionRT combines the latest innovations in molecular biology with risk-based assessment results to assess a woman’s individual tumor biology along with other pathological risk factors and provide a personalized risk of recurrence.The test provides a Decision ScoreTM that identifies a woman’s risk as low or high DCISionRT’s intelligent reporting provides a woman’s risk of recurrence after breast-conserving surgery alone and with radiation therapy in addition. This new information can in turn help patients and their doctors to better understand their behavior make development decisions

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to caring for breast cancer patients worldwide. Founded in 2009 using technology licensed from the University of California at San Francisco, PreludeDx has focused on developing precise breast cancer tools that Affect a Patient’s Treatment Decision Our mission is to provide patients and clinicians with innovative technologies that improve patient outcomes and reduce the overall cost burden on the healthcare system Before making a treatment decision, know your risk TM More information on how PreludeDx works for Patients Makes a Difference, please visit the company’s website: https://preludedxcom and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, the DCI S-Test, Know Your Risk, and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly-owned subsidiaries in the United States and abroad

Breast Cancer, Ductal Cancer In Situ, GenesisCare, Radiation Therapy

News – AU – GenesisCare and PreludeDx ™ partners offer early intervention women access to groundbreaking precision stage breast cancer testing
Related title :
GenesisCare and PreludeDx ™ work together to provide women with access to breakthrough precision testing